DUBLIN--(BUSINESS WIRE)--The "Global RSV Vaccine and Antibody Pipeline Market: Analysis By End User, By Type, By Region, Size and Trends to 2028" report has been added to ResearchAndMarkets.com's offering.
RSV vaccine development has made significant progress during the last ten years. The RSV vaccine and antibody market is expected to grow at a CAGR of 38.90% during the years 2024-2028.
As several vaccines and antibodies are near their last stage readouts, the commercialization and launch of some of these is expected by 2024. The estimates are done for the period, 2024 to 2028. Considering both the modalities (antibody and vaccine) targeting all three key age groups, the global RSV vaccine and antibody market is expected to be worth US$2.56 billion in 2024, rising to US$9.53 billion in 2028.
Market Segmentation Analysis:
- By Type: The report provides the bifurcation of respiratory syncytial virus vaccine and antibody market into two segments on the basis of type: Vaccine and Antibody. In 2024, the vaccine segment is foreseen to lead the respiratory syncytial virus vaccine and antibody market, accounting for 67.5% share of the market as several vaccines candidates trials are near the last stage readouts and their launch is expected soon. Adult vaccination can also help in preventing RSV infection in children when a susceptible child is surrounded by vaccinated people, providing a localised herd immunity effect.
- By End User: The report identifies two segments on the basis of end user: Adult, and Maternal And Pediatric. The adult segment is likely to dominate the respiratory syncytial virus vaccine and antibody market in 2024, with 59.08% share of the market. The rising incidence of RSV in older and immunocompromised adults has gained a lot of traction over the years, and several major players have begun adult vaccine and antibody trials, which is seen as a key factor in giving the adult segment a dominant share.
- By Region: In the report, the global respiratory syncytial virus vaccine and antibody market is divided into three regions: The US, Europe, and ROW. The US is projected to dominate the market in 2024 by occupying almost half of the share of the global market. The most important factor driving the respiratory syncytial virus vaccine and antibody market in the US is rising prevalence of RSV. Moreover, presence of major players and good healthcare facilities in the region would boost the US respiratory syncytial virus vaccine and antibody market in the years to come. Europe respiratory syncytial virus vaccine and antibody market provides lucrative opportunities in the coming years.
Impact Analysis of COVID-19 and Way Forward:
RSV epidemiology has changed substantially as a result of the COVID-19 pandemic. In fact, the RSV season in 2020 was short or non-existent in many areas, with only a few cases. Trial recruitment had largely paused while numerous immunization protocols for COVID-19 were being developed. The RSV season in the US is usually assumed to begin in October and peak between late December and mid-February, however this has altered to a later date. The CDC has noticed that a recent rise in RSV cases, which is generally rarely seen in the summer, has drastically altered the RSV research environment. While the COVID-19 pandemic pushed vaccine development to the forefront, it also slowed clinical research in several therapeutic areas, such as RSV.
The key players of the global respiratory syncytial virus vaccine and antibody market are
- Johnson & Johnson
- Pfizer
- GlaxoSmithKline
- AstraZeneca
- Merck & Co.
- Sanofi
- Bavarian Nordic
- Moderna
- Meissa Vaccines
- Advaccine
- Codagenix
Key Topics Covered:
1. Executive Summary
2. Introduction
2.1 RSV Vaccine & Antibody: An Overview
2.2 RSV Vaccine & Antibody Segmentation
3. Global Market Analysis
3.1 Global RSV Vaccine And Antibody Market: An Analysis
3.2 Global RSV Vaccine And Antibody Market: End User Analysis
3.3 Global RSV Vaccine And Antibody Market: Type Analysis
3.4 Global RSV Vaccine Market: End User Analysis
4. Regional Market Analysis
4.1 The US RSV Vaccine and Antibody Market
4.2 Europe RSV Vaccine and Antibody Market
4.3 ROW RSV Vaccine and Antibody Market
5. Impact of COVID-19
5.1 Impact of COVID-19
5.1.1 Impact of COVID-19 on Healthcare
5.1.2 Impact of COVID-19 Restrictions on RSV Transmission
5.1.3 Impact of COVID-19 on RSV Vaccine and Antibody Market
6. Market Dynamics
6.1 Growth Drivers
6.1.1 Rapid Urbanization
6.1.2 Increasing Geriatric Population
6.1.3 Increasing Healthcare Expenditure
6.1.4 Rising Prevalence of Respiratory Syncytial Virus
6.1.5 Greater Unmet Need
6.1.6 Growing Instances of RSV Among Infants
6.1.7 Favorable Government Support
6.2 Challenges
6.2.1 High Cost of Vaccine Development
6.2.2 Inequitable Access to Vaccines
6.3 Market Trends
6.3.1 Use of AI in Vaccine and Drug Design
6.3.2 Technological Advancements in Vaccine Administration
6.3.3 Competitive Pipeline
7. Competitive Landscape
7.1 Global RSV Vaccine And Antibody Market: Vaccine & Antibody Candidates
7.2 Global RSV Vaccine And Antibody Players By Market Share
7.3 Global RSV Vaccine And Antibody Market: Current Landscape
8. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/r/6r0jtq
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
